Regulated information

Information relative au code de gouvernance

Lors de la réunion du Conseil d’administration du 16 décembre 2014, les administrateurs ont adopté le code de gouvernance Middlenext. Depuis 2008, Vétoquinol se référait au code AFEP-MEDEF.

Information relative au Code de Gouvernance (french)

Lors de la réunion du Conseil d’administration du 16 décembre 2014, les
administrateurs ont adopté le code de gouvernance Middlenext. Depuis
2008, Vétoquinol se référait au code AFEP-MEDEF.

Q3 2014 sales up 11.0%

The Vétoquinol Group reported Q3 2014 sales of €82.2 million, up 11.0% compared to the same period last year (up 11.1% at constant exchange rates).

Solid growth in Q2 2014: 8.8% first half net income up 4.2%

At its July 30, 2014 meeting, the Vétoquinol S.A. Board of Directors reviewed the Group results and approved the financial statements for the first six months of 2014.

Vétoquinol and Bioniche Life Sciences Inc. close sale of Bioniche Animal Health business

Lure, France and Belleville, Ontario, Canada, April 16, 2014 - Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced the closing of the sale of Bioniche’s Animal Health business to Vétoquinol. The two companies announced the signing of a share purchase agreement in February that was subject to the approval of Bioniche shareholders. At a Special Meeting of Shareholders held yesterday, 97.4% of the Shares that were voted were in favour of the transaction.

Reference products up 2.2% in Q1 2014

Lure, April 16, 2013 – Vétoquinol posted Q1 2013 sales of €75.5 million, compared to €77.0 million for the first quarter of 2012. Like-for-like sales amounted to €76.0 million, compared to €77.0 million in Q1 2012.

Vétoquinol is eligible for new PEA-PME funds

Lure (France), April 2, 2014 – Vétoquinol confirms that it qualifies for the PEA-PME investment product in accordance with Decree n°. 2014-283 on 4 March 2014 reflecting the application of Article 70 of 2014 finance law (n°. 2013-1278 dated 29 December 2013) which set the conditions of companies’ eligibility for the PEA-PME

2013 growth driven by reference products

Lure (France), March 12, 2014 – At its March 11, 2014 meeting, the Vétoquinol SA board of directors reviewed the Group results and approved the 2013 financial statements.

Vétoquinol to acquire the animal health business of Bioniche Life Sciences Inc.

LURE, FRANCE and BELLEVILLE, ONTARIO, CANADA, February 27, 2014 - Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced their signing of a share purchase agreement under which Vétoquinol has agreed to purchase Bioniche’s Animal Health business for the cash purchase price of CAD$61 million.

7.8% organic growth in Q4 2013

The Vétoquinol Group posted Q4 2013 sales of €80.1 million, up +7.8% like for like from Q4 2012.

Jean-Yves RAVINET appointed Group Chief Operating Officer

Lure (France), January 7, 2014 – The Vétoquinol Group announces the appointment of Jean-Yves Ravinet as Group Chief Operating Officer.

Q3 2011 Sales

Vétoquinol achieved Q3 2011 sales of €68.4 million, in line with the previous year.

Jacques du Puy appointed Vétoquinol Managing Director

Lure (France), October 12, 2011 – The Vétoquinol Group announces the appointment
of Jacques du Puy as Managing Director.

Forcyl®: european launch of new drug

Lure (France), September 29, 2011 – Vétoquinol announces the European launch of Forcyl®, a new drug based on 16% concentrated marbofloxacin allowing the treatment of cattle respiratory infections with a single injection.

Vétoquinol continues to develop its product ranges and enters the brazilian market

Lure (France), August 30, 2011 – The Vetoquinol Board Meeting of August 29, 2011 reviewed the Group’s business and approved the financial statements for the first half 2011.

International expansion and new product launches

Lure (France), July 19, 2011 – Vétoquinol Group sales rose to €139.7 million in the first six months of 2011.

European launch of new Nsaid Cimalgex®

Lure (France), June 14, 2011 – Vetoquinol announces the European launch of CIMALGEX®, a new treatment for pain and inflammation in dogs.

VÉTOQUINOL enters the brazilian Market

Lure (France), June 7, 2011 – Vetoquinol announces the acquisition of 100% of the equity of Farmagricola SA in Brazil.

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2010 (french version)

The registration document of Vétoquinol relative to fiscal year 2010, including the annual financial report relative to fiscal year 2010, was registered with the Autorité des marchés financiers (“the AMF”) on April 18th, 2011.

Net Sales rise 3% to €66.4 Million in the first Quarter of 2011

The Vétoquinol group reported a 3.0% rise in first quarter 2011 net sales to €66.4 million, compared to the same period last year.

2010 annual earnings

Lure (France), April 4, 2011 – Vétoquinol’s Board of Directors, meeting on March 18, 2011, has reviewed the Group’s business and approved its 2010 financial statements.

Redemption of tranche B bonds

Lure, 28 February 2011 – Vétoquinol S.A. has announced the redemption of the 58,927 tranche B bonds reaching maturity on 27 February 2011, by their conversion into common shares.

2010 Revenues grow 11.8%, driven by organic growth

The Vétoquinol Group reports sustained sales growth driven by its “hybrid” business model, supported by a sound level of organic growth.